IL6R and metabolic syndrome: Previous studies have suggested that circulating levels of sIL-6-R and sgp130 are associated with the risk of inflammation-related diseases, such as CVE and metabolic syndrome (Weiss et al., 2013; Moreno Velasquez et al., 2015; Ritschel et al., 2016).